[(2-{[2-(bis-carboxymethyl-amino)-cyclohexyl]-carboxymethyl-amino}-ethyl)-carboxymethyl-amino]-acetic acid | 3565-84-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2-{[2-(bis-carboxymethyl-amino)-cyclohexyl]-carboxymethyl-amino}-ethyl)-carboxymethyl-amino]-acetic acid
• 英文别名: N-[2-[bis(carboxymethyl)amino]cyclohexyl]-N'-(carboxymethyl)-N,N'-ethylenediglycine；2-[2-[[2-[Bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
• CAS: 3565-84-2
• 化学式: C₁₈H₂₉N₃O₁₀
• 分子量: 447.442
• InChiKey: AOBBBGYEGNXRPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.2
• 重原子数：
  31
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  196
• 氢给体数：
  5
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  [(2-{[2-(bis-carboxymethyl-amino)-cyclohexyl]-carboxymethyl-amino}-ethyl)-carboxymethyl-amino]-acetic acid 、 tetraiodobismutate(III)(1-) 以 further solvent(s) 为溶剂， 生成
  参考文献：
  名称：

  An effective chelating agent for labelling of monoclonal antibody with²¹²Bi for α-particle mediated radioimmunotherapy

  摘要：

  配体 N-[2-氨基-3-(对异硫氰酸苯基)丙基]-(±)-反式-1,2-二氨基环己烷-N,N-2,N-3-五乙酸已合成并连接到IgG 和单克隆抗体 B72.3，并用 206Bi 和 212Bi 标记，以证明标记的体内稳定性及其在 212Bi 放射免疫治疗中的实用性。

  DOI：

  10.1039/c39910001169

文献信息

• [EN] RADIOLABELLED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS D'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) RADIOMARQUÉS ET LEUR UTILISATION
  申请人：3B PHARMACEUTICALS GMBH

  公开号：WO2022123462A1

  公开（公告）日：2022-06-16

  The present disclosure is related to a compound of Formula 1 Wherein R is H or an effector domain which optionally comprises a linker.

  本公开涉及一种化合物，其化学式为1式，其中R为H或一个可选包含连接基的效应区。
• Diagnostic imaging compositions, their methods of synthesis and use
  申请人：——

  公开号：US20030003048A1

  公开（公告）日：2003-01-02

  Conjugate molecules comprising a ligand bonded to a polymer are disclosed. One such conjugate molecule comprises a ligand bonded to a polymer, a chelating agent bonded to the polymer, and a radioisotope chelated to the chelating agent. The conjugate molecules may be useful in detecting and/or treating tumors or biological receptors. These conjugate molecules may be synthesized without the necessity of preactivation of the ligand using an SCN-polymer-chelating agent precursor. Conjugate molecules incorporating an annexin V ligand are particularly useful for visualizing apoptotic cells. Conjugate molecules incorporating a C225 ligand are particularly useful for targeting tumors expressing EGFR.

  本发明公开了由与聚合物结合的配体组成的共轭分子。其中一种共轭分子包括与聚合物结合的配体、与聚合物结合的螯合剂以及与螯合剂螯合的放射性同位素。共轭分子可用于检测和/或治疗肿瘤或生物受体。这些共轭分子的合成无需使用 SCN 聚合物-螯合剂前体对配体进行预激活。含有附件素 V 配体的共轭分子尤其适用于观察凋亡细胞。含有 C225 配体的共轭分子尤其适用于靶向表达表皮生长因子受体的肿瘤。
• DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE
  申请人：Board of Regents,The University of Texas System

  公开号：EP1389090A2

  公开（公告）日：2004-02-18
• CONJUGATES FOR DUAL IMAGING AND RADIOCHEMOTHERAPY: COMPOSITION, MANUFACTURING, AND APPLICATIONS
  申请人：Board of Regents, The University of Texas System

  公开号：EP1846042A2

  公开（公告）日：2007-10-24
• Trifunctional reagent for conjugation to a biomolecule
  申请人：Wilbur Scott D.

  公开号：US20070071673A1

  公开（公告）日：2007-03-29

  A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.